Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 44

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 44
---
 of common stock outstanding as of December 31, 2024, and excludes the following potentially dilutive securities as of that date:

| ● | 2,352,670                                                                                                                         
 shares of common stock issuable upon the exercise of stock options outstanding, under our equity incentive plans, with a weighted 
 average exercise price of $5.02 per share;                                                                                        |

| ● | 4,147,330                                                                                
 shares of common stock available for future grants under our equity incentive plans; and |

| ● | 2,814,057                                                                                                                             
 shares of common stock issuable upon the exercise of warrants outstanding, with a weighted average exercise price of $4.97 per share. |

To the extent that any of these options, awards or warrants are exercised, new options and awards are issued under our equity incentive plans and subsequently exercised or we issue additional common stock or securities convertible into common stock in the future, there may be further dilution to new investors participating in this offering.

| Alt-14 |

<div align='center'>DIVIDENDS</div>

In the past, we have not declared or paid cash dividends on our common stock, and we do not intend to pay any cash dividends on our common stock. Rather, we intend to retain future earnings, if any, to fund the operation and expansion of our business and for general corporate purposes.

<div align='center'>PLAN OF DISTRIBUTION</div>

We entered into the sales agreement with Rodman & Renshaw, pursuant to which such agreement and this prospectus and the accompanying base prospectus, we may issue and sell from time to time shares of our common stock having an aggregate offering price of up to $100,000,000 through Rodman & Renshaw as our sales agent. Sales of the common stock, if any, will be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Capital Market, the trading market for our common stock, or any other existing trading market in the United States for our common stock, or sales made to or through a market maker other than on an exchange.

If we and Rodman & Renshaw agree on any method of distribution other than sales of shares of our common stock on the Nasdaq Capital Market or another existing trading market in the United States at market prices, we will file a prospectus supplement providing all information about such offering as required